NUROSENE HEALTH INC. ANNOUNCES CLOSING OF PRIVATE PLACEMENT
NUROSENE HEALTH INC. ANNOUNCES CLOSING OF PRIVATE PLACEMENT
TORONTO, Oct. 14, 2022 /PRNewswire/ - Nurosene Health Inc. ("Nurosene" or the "Company") (CSE: MEND) (Frankfurt: 8TV) (OTC: MNNDF), is pleased to announce that it has completed a closing of a non-brokered private placement in which it issued 2,910,000 units (the "Units") at a price of $0.25 per Unit for aggregate gross proceeds to Nurosene of
多倫多,2022年10月14日/美通社/-紐羅森健康公司。(“紐羅森”或“公司”)(CSE：MEND)(法蘭克福：8TV)(場外交易代碼：MNNDF)高興地宣佈，它已經完成了一項非中介私募的結束，在該私募中，它發行了2,910,000個單位(“單位”)，發行價為$0.25每單位對紐羅森的總收益
$727,500. Each of the Units is comprised of one common share (each a "Common Share") and one common share purchase warrant (each a "Warrant"). Each Warrant entitles its holder to acquire one additional Common Share at a price of $0.40 for a period of 36 months from the closing date. Nurosene intends to use the net proceeds from the private placement for working capital purposes.
727,500美元。每個單位由一股普通股(每股為“普通股”)和一份普通股認購權證(每股為“認股權證”)組成。每份認股權證使其持有人有權以0.40美元的價格額外購買一股普通股，有效期為36個月，自截止日期起計。Nurosene打算將私募所得淨額用於營運資本目的。
Two directors and one officer of Nurosene (the "Insiders") purchased, indirectly, an aggregate of 840,000 Units for a total consideration of $210,000. The issuance of Units to the Insiders constitutes a related party transaction, but is exempt from the formal valuation and minority approval requirements of Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101") as Nurosene' securities are not listed on any stock exchange identified in Section 5.5(b) of MI 61-101 and neither the fair market value of the Units issued to the Insiders, nor the fair market value of the entire private placement, exceeds 25% of Nurosene' market capitalization. Nurosene did not file a material change report with respect to the participation of the Insiders at least 21 days prior to the closing of the private placement as the insider participation was not determined at that time.
Nurosene的兩名董事和一名高級職員(“內部人士”)間接購買了總計840,000個單位，總代價為210,000美元。向內部人士發行單位構成關聯方交易，但不受多邊文書61-101的正式估值和少數股東批准的要求-特殊交易中少數股權持有人的保護(“MI 61-101”)，因為紐森的證券並不在MI 61-101第5.5(B)節所指的任何證券交易所上市，而向內部人士發行的單位的公平市價或整個私募的公平市價均不超過紐森市值的25%。至少在私募結束前21天，Nurosene沒有就內部人士的參與提交重大變化報告，因為當時尚未確定內部人士的參與。
In connection with the closing of the private placement, the Company paid finder's fee commissions in the aggregate amount of $34,475 and issued 137,900 broker warrants (each, a "Broker Warrant"). Each Broker Warrant entitles the holder thereof to purchase one Common Share at an exercise price of $0.40 per share for a period of 36 months from the closing date.
關於私募的結束，本公司支付了總金額為34,475美元的找尋費用佣金，併發行了137,900份經紀認股權證(每份為“經紀認股權證”)。每份經紀認股權證的持有人有權按行使價$0.40自截止日期起計的36個月期間內每股。
The securities issued by the Company in connection with this financing will be subject to a 4-month and a day "hold period" expiring February 14, 2023, as prescribed by applicable securities laws.
根據適用證券法的規定，公司發行的與此次融資相關的證券將有4個月零1天的“持有期”，截止日期為2023年2月14日。
As a result of closing the private placement, there are 45,431,102 Common Shares of Nurosene issued and outstanding.
作為私募結束的結果，紐羅森已發行和已發行的普通股有45,431,102股。
Nurosene is a company focused on the development of AI-Healthtech solutions for the Health and Wellness, Neurodegenerative and Oncology markets We have developed an ecosystem of innovative products that directly support brain-related conditions. Our world- renowned team and partners are disrupting traditional mental wellness treatments and are positioned at the forefront of critical research and innovations. NetraMark, a wholly owned subsidiary of Nurosene Health Inc., is providing proprietary next-generation AI solutions for pharmaceutical and biotechnology companies across the spectrum of disease.
Nurosene是一家專注於為健康和健康、神經退行性疾病和腫瘤學市場開發AI-Healthtech解決方案的公司。我們已經開發了一個創新產品生態系統，直接支持與大腦相關的疾病。我們世界知名的團隊和合作夥伴正在顛覆傳統的心理健康治療，並處於關鍵研究和創新的前沿。Nurosene Health Inc.的全資子公司NetraMark正在為各種疾病的製藥和生物技術公司提供專有的下一代人工智能解決方案。
This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation regarding use of proceeds which is based upon Nurosene's current internal expectations, estimates, projections, assumptions and beliefs, and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as "expect", "likely", "may", "will", "should", "intend", "anticipate", "potential", "proposed", "estimate" and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions "may", "would" or "will" happen, or by discussions of strategy. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact.
本新聞稿包含適用於加拿大證券法的有關收益使用的“前瞻性信息”，這些信息基於Nurosene公司目前的內部預期、估計、預測、假設和信念以及對未來事件的看法。前瞻性信息可以通過使用“預期”、“可能”、“可能”、“將”、“應該”、“打算”、“預期”、“潛在”、“建議”、“估計”和其他類似詞語，包括其否定和語法變化，或某些事件或條件“可能”、“將”或“將”發生的陳述，或通過討論戰略來確定。前瞻性信息包括估計、計劃、預期、意見、預測、預測、目標、指導或其他非事實陳述。
Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, Nurosene does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise. New factors emerge from time to time, and it is not possible for Nurosene to predict all such factors. When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements in Nurosene's Final Long Form Prospectus dated May 20, 2021 and Management's Discussion and Analysis for the year ended September 30, 2021 ("MD&A"), and filed with the applicable Canadian securities regulatory authorities on SEDAR at . The risk factors and other factors noted in Nurosene's Final Long Form Prospectus and MD&A could cause actual events or results to differ materially from those described in any forward-looking information.
任何前瞻性信息僅在發佈之日發表，除非法律另有要求，紐羅森不承擔任何義務更新或修改任何前瞻性信息，無論是由於新信息、未來事件或其他原因。新的因素不時出現，紐森不可能預測到所有這些因素。在考慮這些前瞻性陳述時，讀者應牢記諾羅森公司2021年5月20日的最終長篇説明書中的風險因素和其他警告性陳述，以及管理層對截至年底的討論和分析2021年9月30日(“MD&A”)，並在SEDAR上向適用的加拿大證券監管機構提交。紐森的最終長篇招股説明書和MD&A中提到的風險因素和其他因素可能會導致實際事件或結果與任何前瞻性信息中描述的大不相同。
The CSE does not accept responsibility for the adequacy or accuracy of this release.
CSE不對本新聞稿的充分性或準確性承擔責任。
SOURCE Nurosene Health Inc.
來源：Nurosene Health Inc.
譯文內容由第三人軟體翻譯。